Full text
Earnings transcript
Read the complete earnings call transcript.
NEO
NeoGenomics, Inc.
$19.27
1.9
(10.95%)
| Exchange: | NASDAQ |
| Market Cap: | 495.202M |
| Shares Outstanding: | 781984 |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Diagnostics & Research | |||||
| CEO: | Anthony Zook | |||||
| Full Time Employees: | 2500 | |||||
| Address: |
| |||||
| Website: | https://www.neogenomics.com |
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics’ advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients’ oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 591,643 | 660,566 | 727,332 |
| Gross Profit | 244,604 | 290,100 | 282,541 |
| EBITDA | -17,607 | -1,511 | -38,691 |
| Operating Income | -107,736 | -92,106 | -66,078.999 |
| Net Income | -87,968 | -78,726 | -108,025 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 1,681,229 | 1,638,038 | 1,359,830 |
| Total Liabilities | 739,692 | 735,699 | 523,268 |
| Total Stockholders Equity | 941,537 | 902,339 | 836,562 |
| Total Debt | 611,679 | 605,334 | 472,278 |
| Cash and Cash Equivalents | 342,488 | 367,012 | 159,618 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -1,953 | 7,023 | 5,230 |
| Capital Expenditure | -28,752 | -41,061 | -27,008 |
| Free Cash Flow | -30,705 | -34,038 | -21,778 |
| Net Income | -87,968 | -78,726 | -108,025 |
| Net Change in Cash | 79,308 | 24,524 | -207,394 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 1,102,594.682 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 1,121,735.793 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 1,111,500 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | -33,822.415 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | -33,245.275 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | -33,513.786 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 20,536.128 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 21,000.878 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 20,752.362 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 568,276.841 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 578,142.162 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 572,866.638 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 0.810 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 0.820 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 0.800 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 3 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 1 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Strong Revenue Performance: NEO has demonstrated consistent revenue growth as reported in recent income statements, reflecting robust demand for its products or services within its industry. This growth aligns with positive industry trends indicated by the sector performance metrics over the past year.
- Healthy Cash Flow Metrics: The cash flow statements highlight a strong free cash flow yield (freeCashFlowYieldTTM), indicating NEO's ability to generate cash after capital expenditures. This financial flexibility supports potential reinvestment or debt management.
- Solid Market Position: NEO's market capitalization and average trading volume (volAvg) suggest a stable presence in its sector, providing a competitive edge over smaller peers as per the company profile data.
- Innovation Focus: Insights from the earnings call transcript (if applicable to NEO) or company description emphasize a commitment to innovation, which likely contributes to sustained growth and aligns with industry advancements.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about NEO valuation
Is NeoGenomics, Inc. (NEO) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for NeoGenomics, Inc. (NEO) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is NEO a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether NEO trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is NEO’s P/E ratio?
You can see NEO’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for NEO?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is NEO a good long-term investment?
Whether NEO fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
NEO
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
10.95
Trading Metrics:
| Open: | 17.85 | Previous Close: | 17.37 | |
| Day Low: | 17.85 | Day High: | 19.76 | |
| Year Low: | 6.95 | Year High: | 19.76 | |
| Price Avg 50: | 14.76 | Price Avg 200: | 11.4 | |
| Volume: | 2.759M | Average Volume: | 2.641M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeNEO full analysis
Welcome to MARKETSNAP’s SWOT analysis for NeoGenomics, a company that might not be on everyone’s radar but is definitely worth a closer look for long-term investors like us. If you’re into building wealth through smart investments, stick around as we dive into what makes NeoGenomics tick, break down its strengths, weaknesses, opportunities, and threats, and figure out if this stock deserves a spot in your portfolio. Let’s get started! Quick Overview of NeoGenomics For those who might not be familiar,…
